TORONTO, Aug. 19 /CNW/ - Amorfix Life Sciences, a company focused on
treatments and diagnostics for brain wasting diseases, announced today that it
will set up the EP-vCJD(TM) assay system in the Prion Laboratory at the
British National Institute for Biological Standards and Controls (NIBSC)
outside London and begin to test fresh human blood samples as part of the
ongoing assay validation process announced earlier this year. Based on the
performance of its EP-vCJD(TM) assay, Amorfix received and accepted an
invitation from the British government to further qualify the specificity of
the assay using British blood donor samples to be supplied by the National
Blood Service.
